14 Best 52-Week High Stocks To Buy According to Analysts

2. Delcath Systems, Inc. (NASDAQ:DCTH)

52 Week Range: $3.70 – $13.30

Current Share Price: $12.69

Stock Upside Potential: 73.32%

Number of Hedge Fund Holders: 17

Delcath Systems, Inc. (NASDAQ:DCTH) is an interventional oncology company that focuses on the treatment of primary and metastatic liver cancers. The company’s lead product candidate is HEPZATO KIT, designed to administer high-dose chemotherapy to the liver. After rallying by more than 200% in 2024, the stock has started 2025 on a roll and trading close to its 52-week highs.

Delcath Systems, Inc. (NASDAQ:DCTH) remains one of the best 52-week high stocks to buy, according to analysts, on the back of solid financial results characterized by record sales in recent quarters. The record sales come on strong adoption of the company’s HEPZATO kit, affirming growing market acceptance of the product.

Delcath Systems, Inc. (NASDAQ:DCTH) is projecting revenues of $15.1 million for its fourth quarter against $12.4 million, which analysts expect will continue to strengthen its sentiments in the market. The specialty pharmaceutical company also projects full-year sales of $37.2 million against the expected $34.5 million. The better-than-expected sales numbers affirm that Delcath Systems expects continued growth and strong market position in 2025 as in 2024. The success of the HEPZATO launch and the sequential revenue growth demonstrate strong market adoption. According to the product mix, HEPZATO generates 87% of total revenues and CHEMOSAT 13%, demonstrating successful market penetration in the US.